117 related articles for article (PubMed ID: 7828652)
21. 1,4-Dihydropyridine activators in the tiamdipine series.
Galletti F; Luchowski E; Triggle DJ
Eur J Pharmacol; 1990 Aug; 185(2-3):157-61. PubMed ID: 2147653
[TBL] [Abstract][Full Text] [Related]
22. Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes.
Corsini A; Bonfatti M; Quarato P; Accomazzo MR; Raiteri M; Sartani A; Testa R; Nicosia S; Paoletti R; Fumagalli R
J Cardiovasc Pharmacol; 1996 Nov; 28(5):687-94. PubMed ID: 8945683
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological properties of voltage-dependent calcium channels in functional microvessels isolated from rat brain.
Morel N; Godfraind T
Naunyn Schmiedebergs Arch Pharmacol; 1989 Oct; 340(4):442-51. PubMed ID: 2555723
[TBL] [Abstract][Full Text] [Related]
24. Modulation of [3H]dihydropyridine binding by activation of protein kinase C in vascular smooth muscle.
Mironneau C; Rakotoarisoa L; Sayet I; Mironneau J
Eur J Pharmacol; 1991 Nov; 208(3):223-30. PubMed ID: 1663046
[TBL] [Abstract][Full Text] [Related]
25. Ca2+ channel activation and membrane depolarization mediated by Cl- channels in response to noradrenaline in vascular myocytes.
Pacaud P; Loirand G; Baron A; Mironneau C; Mironneau J
Br J Pharmacol; 1991 Dec; 104(4):1000-6. PubMed ID: 1667281
[TBL] [Abstract][Full Text] [Related]
26. A comparison between the binding and electrophysiological effects of dihydropyridines on cardiac membranes.
Hamilton SL; Yatani A; Brush K; Schwartz A; Brown AM
Mol Pharmacol; 1987 Mar; 31(3):221-31. PubMed ID: 2436031
[TBL] [Abstract][Full Text] [Related]
27. Key roles of Phe1112 and Ser1115 in the pore-forming IIIS5-S6 linker of L-type Ca2+ channel alpha1C subunit (CaV 1.2) in binding of dihydropyridines and action of Ca2+ channel agonists.
Yamaguchi S; Zhorov BS; Yoshioka K; Nagao T; Ichijo H; Adachi-Akahane S
Mol Pharmacol; 2003 Aug; 64(2):235-48. PubMed ID: 12869628
[TBL] [Abstract][Full Text] [Related]
28. Dual effect of thrombin on voltage-dependent Ca2+ channels of portal vein smooth muscle cells.
Baron A; Loirand G; Pacaud P; Mironneau C; Mironneau J
Circ Res; 1993 Jun; 72(6):1317-25. PubMed ID: 8388325
[TBL] [Abstract][Full Text] [Related]
29. L-type Ca2+ channels activation and contraction elicited by myricetin on vascular smooth muscles.
Fusi F; Saponara S; Frosini M; Gorelli B; Sgaragli G
Naunyn Schmiedebergs Arch Pharmacol; 2003 Dec; 368(6):470-8. PubMed ID: 14618297
[TBL] [Abstract][Full Text] [Related]
30. Effects of calcium entry blockers on calcium-dependent contractions of rat portal vein.
Dacquet C; Mironneau C; Mironneau J
Br J Pharmacol; 1987 Sep; 92(1):203-11. PubMed ID: 2959345
[TBL] [Abstract][Full Text] [Related]
31. Prolonged depolarization increases the pharmacological effect of dihydropyridines and their binding affinity for calcium channels of vascular smooth muscle.
Morel N; Godfraind T
J Pharmacol Exp Ther; 1987 Nov; 243(2):711-5. PubMed ID: 2824756
[TBL] [Abstract][Full Text] [Related]
32. Permanently charged chiral 1,4-dihydropyridines: molecular probes of L-type calcium channels. Synthesis and pharmacological characterization of methyl(omega-trimethylalkylammonium) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate iodide, calcium channel antagonists.
Peri R; Padmanabhan S; Rutledge A; Singh S; Triggle DJ
J Med Chem; 2000 Jul; 43(15):2906-14. PubMed ID: 10956198
[TBL] [Abstract][Full Text] [Related]
33. The interactions of 1,4-dihydropyridines bearing a 2-(2-aminoethylthio)methyl substituent at voltage-dependent Ca2+ channels of smooth muscle, cardiac muscle and neuronal tissues.
Kwon YW; Zhong Q; Wei XY; Zheng W; Triggle DJ
Naunyn Schmiedebergs Arch Pharmacol; 1990; 341(1-2):128-36. PubMed ID: 2156174
[TBL] [Abstract][Full Text] [Related]
34. Ca2+ channel modulation alters halothane-induced depression of ventricular myocytes.
Kanaya N; Matsumoto M; Kawana S; Tsuchida H; Kimura H; Miyamoto A; Ohshika H; Namiki A
Can J Anaesth; 1998 Jun; 45(6):584-91. PubMed ID: 9669017
[TBL] [Abstract][Full Text] [Related]
35. Selective modulation by membrane potential of desmethoxyverapamil binding to calcium channels in rat portal vein.
Rakotoarisoa L; Sayet I; Mironneau C; Mironneau J
J Pharmacol Exp Ther; 1990 Dec; 255(3):942-7. PubMed ID: 2175807
[TBL] [Abstract][Full Text] [Related]
36. The voltage-dependent effect of 1,4-dihydropyridine enantiomers on Ca channels in cardiac cells.
Kokubun S; Porzig H; Prod'hom B; Reuter H
Jpn Heart J; 1986 Nov; 27 Suppl 1():57-63. PubMed ID: 2434682
[TBL] [Abstract][Full Text] [Related]
37. Activation of L-type Ca2+ channels after purinoceptor stimulation by ATP in an alveolar epithelial cell (L2).
Dietl P; Haller T; Wirleitner B; Völkl H; Friedrich F; Striessnig J
Am J Physiol; 1995 Dec; 269(6 Pt 1):L873-83. PubMed ID: 8572250
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca2+ channel activator, in cardiac and vascular preparations.
Zheng W; Rampe D; Triggle DJ
Mol Pharmacol; 1991 Nov; 40(5):734-41. PubMed ID: 1719369
[TBL] [Abstract][Full Text] [Related]
39. Ca2+ channel inhibition in a rat osteoblast-like cell line, UMR 106, by a new dihydropyridine derivative, S11568.
Morain P; Peglion JL; Giesen-Crouse E
Eur J Pharmacol; 1992 Sep; 220(1):11-7. PubMed ID: 1385178
[TBL] [Abstract][Full Text] [Related]
40. Motif III S5 of L-type calcium channels is involved in the dihydropyridine binding site. A combined radioligand binding and electrophysiological study.
He M; Bodi I; Mikala G; Schwartz A
J Biol Chem; 1997 Jan; 272(5):2629-33. PubMed ID: 9006896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
